The role of receptor activity-modifying proteins in obesity and diabetes mellitus.

Autor: Malcharek MA; Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom., Pearce A; Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom., Brighton CA; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Hornigold DC; Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Ladds G; Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.

Publikováno v: Journal of molecular endocrinology [J Mol Endocrinol] 2024 Oct 30; Vol. 73 (4). Date of Electronic Publication: 2024 Oct 30 (Print Publication: 2024).

The GPCR adaptor protein Norbin regulates S1PR1 trafficking and the morphology, cell cycle and survival of PC12 cells.

Autor: Johansen VBI; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.; Department of Biology, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Hampson E; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.; Vernalis (R&D) Ltd., Cambridge, UK., Tsonou E; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Pantarelli C; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Chu JY; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Crossland L; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK., Okkenhaug H; Imaging Facility, The Babraham Institute, Cambridge, UK., Massey AJ; Vernalis (R&D) Ltd., Cambridge, UK., Hornigold DC; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Welch HCE; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. heidi.welch@babraham.ac.uk., Chetwynd SA; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK. stephen.chetwynd@babraham.ac.uk.

Publikováno v: Scientific reports [Sci Rep] 2023 Oct 25; Vol. 13 (1), pp. 18237. Date of Electronic Publication: 2023 Oct 25.

Peptide-YY 3-36 /glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries.

Autor: Boland BB; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Gubra ApS, Horsholm, Denmark; PRECISIONscientia, Yardley, PA, USA., Laker RC; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., O'Brien S; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sitaula S; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sermadiras I; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Nielsen JC; Gubra ApS, Horsholm, Denmark., Barkholt P; Gubra ApS, Horsholm, Denmark., Roostalu U; Gubra ApS, Horsholm, Denmark., Hecksher-Sørensen J; Gubra ApS, Horsholm, Denmark., Sejthen SR; Gubra ApS, Horsholm, Denmark., Thorbek DD; Gubra ApS, Horsholm, Denmark., Suckow A; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; DTX Pharma, San Diego, CA, USA., Burmeister N; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Roche, Penzberg, Germany., Oldham S; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Will S; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Howard VG; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Gill BM; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Newton P; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Naylor J; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hornigold DC; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Austin J; University of Chicago Advanced Electron Microscopy Core Facility, Chicago, IL, USA., Lantier L; Vanderbilt University Mouse Metabolic Phenotyping Center, Nashville, TN, USA., McGuinness OP; Vanderbilt University Mouse Metabolic Phenotyping Center, Nashville, TN, USA., Trevaskis JL; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Gilead Sciences, Foster City, CA, USA., Grimsby JS; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Rhodes CJ; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: christopher.rhodes@astrazeneca.com.

Publikováno v: Molecular metabolism [Mol Metab] 2022 Jan; Vol. 55, pp. 101392. Date of Electronic Publication: 2021 Nov 12.

Rho Family GTPases and Rho GEFs in Glucose Homeostasis.

Autor: Machin PA; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK., Tsonou E; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge CB22 3AT, UK., Hornigold DC; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge CB22 3AT, UK., Welch HCE; Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.

Publikováno v: Cells [Cells] 2021 Apr 16; Vol. 10 (4). Date of Electronic Publication: 2021 Apr 16.

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.

Autor: Parker VER; AstraZeneca, Cambridge, England, UK., Robertson D; AstraZeneca, Cambridge, England, UK., Wang T; AstraZeneca, Gaithersburg, MD, USA., Hornigold DC; AstraZeneca, Cambridge, England, UK., Petrone M; AstraZeneca, Cambridge, England, UK., Cooper AT; AstraZeneca, Cambridge, England, UK., Posch MG; Charite Research Organisation GmbH, Berlin, Germany., Heise T; Profil, Neuss, Germany., Plum-Moerschel L; Profil, Mainz, Germany., Schlichthaar H; SMO.MD, Magdeburg, Germany., Klaus B; Nuvisan Pharma Services, Ulm, Germany., Ambery PD; AstraZeneca, Gothenburg, Sweden., Meier JJ; St Josef-Hospital, Ruhr-University, Bochum, Germany., Hirshberg B; AstraZeneca, Gaithersburg, MD, USA.

Publikováno v: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2020 Mar 01; Vol. 105 (3).